Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 May 25;5(6):481-483.
doi: 10.1016/j.jdcr.2019.03.007. eCollection 2019 Jun.

Treatment of estrogen-induced dermatitis with omalizumab

Jesus A Ocana  1 , Maria C Bell  1 , Jordan B Heskett  2 , William H Baker  3   4 , Nico Mousdicas  4 , Matthew J Turner  2   4
Affiliations
Case Reports

Treatment of estrogen-induced dermatitis with omalizumab

Jesus A Ocana et al. JAAD Case Rep. .
No abstract available

Keywords: estrogen-induced dermatitis; mast cells; omalizumab.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Estrogen dermatitis manifesting as arcuate erythematous plaques with trailing scale on medial aspects of the breasts.
See this image and copyright information in PMC

References

    1. Zondek B., Bromberg Y.M. Endocrine allergy. J Allergy. 1945;16(1):1–16.
    1. Shelley W.B., Shelley E.D., Talanin N.Y. Estrogen dermatitis. J Am Acad Dermatol. 1995;32(1):25–31. - PubMed
    1. Perdue N., Ezra N., Mousdicas N. Estrogen dermatitis presenting as gyrate erythema treated with leuprolide. Dermatitis. 2014;25(5):277–278. - PubMed
    1. Sanchez J., Ramirez R., Diez S. Omalizumab beyond asthma. Allergol Immunopathol (Madr) 2012;40(5):306–315. - PubMed
    1. Moon T.C., Befus A.D., Kulka M. Mast cell mediators: their differential release and the secretory pathways involved. Front Immunol. 2014;5:569. - PMC - PubMed

Publication types

LinkOut - more resources